Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Dasatinib in Combination With Trastuzumab and Paclitaxel in the First Line Treatment of Her2-Positive Metastatic Breast Cancer (MBC) Patients

NCT01306942 is registered in ClinicalTrials.gov with Spanish Breast Cancer Research Group as lead sponsor.

NCT NCT01306942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01306942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Dasatinib in Combination With Trastuzumab and Paclitaxel in the First Line Treatment of Her2-Positive Metastatic Breast Cancer (MBC) Patients
Lead sponsor
Spanish Breast Cancer Research Group
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2011
Completion date
March 15, 2019
Enrollment
37 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer